BioNTech Terminates Phase 2 Trial of mRNA Therapy for Colorectal Cancer, Stock Drops Over 6%
nashnova research
BioNTech announced it will terminate the Phase 2 trial of its individualized mRNA cancer therapy autogene cevumeran in colorectal cancer; shares fell as much as 9% intraday before narrowing to a 6.79% decline — a direct hit to market confidence in the mRNA leader's oncology pipeline.
What trial was terminated?
BioNTech halted Phase 2 trial BNT122-01, testing a drug called autogene cevumeran (code name BNT122).
It is an individualized mRNA cancer immunotherapy — a custom mRNA "recipe" designed from each patient's tumor profile to train the immune system to find and attack cancer cells.
The trial enrolled patients with surgically resected stage II (high-risk) or stage III colorectal cancer who were ctDNA-positive (circulating tumor DNA — residual tumor signals still detectable in the blood).
Who made the call?
Autogene cevumeran is co-developed by BioNTech and Genentech, a unit of the Roche Group.
The termination was a joint decision reached after consultation between the two companies — not a unilateral move by BioNTech.
This means → both partners have reached a shared negative verdict on this therapy's prospects in adjuvant colorectal treatment, at least under the current trial design.
Why no explanation?
BioNTech disclosed no specific reason for stopping the trial — no mention of poor efficacy, no mention of safety concerns.
In plain terms = investors got a conclusion with no process: the trial is dead, but no one knows whether the data disappointed, enrollment stalled, or some other commercial calculus drove the decision.
This reflects the still-high uncertainty in bringing mRNA oncology therapies from concept to clinical reality — even when the company behind it has proven mRNA manufacturing at vaccine scale.
How did the market react?
BioNTech shares dropped as much as 9% intraday after the announcement, later narrowing to a 6.79% decline at $103.84.
This means → the market read this termination as a pipeline-level negative, not a trivial project adjustment.
In plain terms = investors who own BioNTech are largely betting on one story — "mRNA technology can expand from vaccines into cancer treatment." A key chapter of that story just got torn out.
市场有风险，内容仅供研究参考，不构成投资建议。